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ADouble-Blind, Placebo-Controlled Trial to Assess Safety
and Tolerability of (Thetanix) Bacteroides
thetaiotaomicron in Adolescent Crohn’s Disease
Richard Hansen, PhD1, Ian R. Sanderson, MD2, Rafeeq Muhammed, MBChB3, Stephen Allen, MD4,5, Christos Tzivinikos, MD5,
Paul Henderson, PhD6,7, Lisa Gervais, BN1, Ian B. Jeffery, PhD8, David P. Mullins, MSc8, Eileen A. O’Herlihy, PhD8,
John D. Weinberg, MBBCh9, Geoff Kitson, MBBS10, Richard K. Russell, PhD6 and David C. Wilson, MD7
INTRODUCTION: Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live
biotherapeutic, under development for Crohn’s disease, that antagonizes transcription factor nuclear
factor kappaB, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha.Weaimed
to assess safety and tolerability in adolescents with Crohn’s disease in remission.
METHODS: Subjects who were 16–18 years with Crohn’s in remission (weighted pediatric Crohn’s disease activity
index <12.5) were recruited. Each active dose comprised ;108.261.4 colony forming units of B.
thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days
twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B.
thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported
adverse events and recorded temperature twice daily.
RESULTS: Fifteen subjects were treated—8 in part A (75%men,median 17.1 years) and 10 in part B, including 3
from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent
immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events
deemed related—one in part A with eructation, flatulence, and reflux; one in part B with dizziness,
abdominal pain, and headache. No serious adverse events were reported. There was no significant
change in median calprotectin across part B (87.8 [4.4–447] to 50.5 [5.3–572], P 5 0.44 by the
Fisher exact test in the active group). No significant differences were found in microbiota profiles, but
diversity seemed to increase in treated subjects.
DISCUSSION: Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were
small, the safety profile seems good. Future studies should explore efficacy.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B800
Clinical and Translational Gastroenterology 2021;12:e00287. https://doi.org/10.14309/ctg.0000000000000287
INTRODUCTION
We stand on the cusp of a potential therapeutic revolution in
inflammatory bowel disease (IBD) management centered on
microbial therapeutics (1,2). The genetic revolution in IBD
pointed firmly to the microbiome as pivotal in disease patho-
genesis, with the seminal study by Jostins and colleagues stating
“Most of the evidence relating to possible causal genes points to
an essential role for host defense against infection in IBD” (3).
Despite this, and progress with fecal microbial transplantation
as a treatment for ulcerative colitis (4,5) and selected antibiotics
(6) andnutritional therapy inCrohn’s disease (CD) (7–9), data on
probiotics as therapy for CD have been disappointing to date
(10,11). One published editorial suggested that the reason for this
disappointment might be because we have not tested the correct
organisms, the correct combination of organisms, the correct
subsets of patients, or perhaps even because our understanding of
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the host–microbe interactions in IBD is flawed (12). Indeed, most
probiotics tested to date tend to have been selected for conve-
nience or ease of manufacture, rather than biological plausibility.
There is, therefore, a need to revisit the potential for targeted
microbial therapy using organisms that may havemore relevance
to the disease, accepting that they may be commercially harder to
work with, including Bacteroides, Faecalibacterium, and Akker-
mansia species (12). This approach has been termed live bio-
therapeutics or next-generation probiotics.
Bacteroides thetaiotaomicron is one such species—a nonmotile,
purely anaerobic symbiotic bacterium—with the ability to digest
dietary fibers and host glycans while producing short chain and
organic acids, and a cell surface that both interacts with and evades
the host immune system (13). The organismhad a sequencing read
prevalence of ;1.5% in a recent longitudinal pediatric CD
microbiome study (14) and has been shown to support and stim-
ulate mucus production within the colon, which may enhance an
important innate immune mechanism against bacterial invasion
(15). B. thetaiotaomicron also attenuates gut inflammation via
enhancement of nuclear factor kappa B (NF-kB) subunit RelA
nuclear export and subsequent antagonism of transcription factor
NF-kB (16). The pivotal importance of NF-kB in driving tumor
necrosis factor alpha (TNFa) release after NOD2 expression
highlights the importance of this transcription factor in CD im-
munopathology (17). B. thetaiotaomicron therefore has potential
as a live biotherapeutic and mucosally active anti-TNFa.
In 2 rodent models of colitis (dextran sodium sulphate [DSS]
and interleukin-10 knockout), B. thetaiotaomicron ameliorated
weight loss, histological damage, and immunological activation,
including reduced expression of TNFa in the DSS model (18).
Importantly, lyophilized B. thetaiotaomicronmaintained similar
levels of efficacy to actively growing bacteria in ameliorating DSS
colitis, suggesting that a lyophilized preparation could prove
useful in treating gastrointestinal inflammation in humans.
Our study’s aim was to assess the safety and tolerability of
B. thetaiotaomicron in patients with CD; therefore, we chose to
perform a first-in-humans safety study of lyophilized B. thetaio-
taomicron (Thetanix) in adolescent patients with known CD in
clinical remission. We opted to test the investigational medicinal
product (IMP) in patients with CD first because the abundance ofB.
thetaiotaomicron in the healthy gutmicrobiomewould likelymake a
healthy volunteer study redundant. This position was agreed with
the United Kingdom’s Medicines and Healthcare Products Regula-
toryAgency before our submission to the regional ethics committee.
MATERIALS AND METHODS
This was a randomized, double-blind, placebo-controlled study
in subjects with CD in remission, aged 16–18 years. The study
started with a single-dose challenge with follow-up for adverse
events (AEs) (part A, n 5 8) and then proceeded to part B, in
which twice daily dosing was provided for 7.5 days (n 5 10).
Patients who participated in part A were also allowed to partici-
pate in part B. Subjects suitable for this study were identified from
current patient lists at pediatric gastroenterology clinics in Royal
Hospital for Children, Glasgow; RoyalHospital for Sick Children,
Edinburgh; Birmingham Children’s Hospital; Alder Hey Child-
ren’s Hospital, Liverpool; and Royal London Hospital. Inclusion
and exclusion criteria were devised to identify patients with stable
CD in remission during late adolescence and were subsequently
amended to allow patients stable on anti-TNFa therapy and after
resection surgery to be included (Box 1). A urine pregnancy test
was completed for all female subjects who were postmenarche.
The recruitment target for both part A and part B was set at 10
participants, with inclusion in both parts acceptable if inclusion/
exclusion criteria could still be achieved after rescreening. The
recruitment target to part A was revised to 8 subjects after a
substantial amendment. A review of all safety data was un-
dertaken by the safety review committee (SRC), comprising the
coordinating investigator, the principle investigators for active
sites, site coinvestigators, and the medical monitor, before pro-
gression to part B was deemed appropriate.
Thetanix is formulated as off-white, intrinsically enteric, size
0 capsules containing lyophilized B. thetaiotaomicron. Each
capsule contains 107.7361.43 colony forming units (CFUs) and
microcrystalline cellulose. Capsules were refrigerated until use. A
single dose of Thetanix consisted of 3 capsules, comprising
108.261.4 CFUs of B. thetaiotaomicron. The placebo capsules
contained microcrystalline cellulose, but no B. thetaiotaomicron
and were equivalent in size, weight, and appearance to the test
formulation. Randomization was performed by an independent
statistician on a 4 active: 1 placebo basis for both parts of the
study. The allocation of kits to participants was performed cen-
trally using an interactive voice/web response allocation system.
The occurrence of AEs was sought by questioning of the
subject during dosing admissions and by completion of a diary
card by subjects after discharge. AEs were checked at follow-up
visits. AEs could have been detected when volunteered by the
subject or through physical examination, laboratory test, or other
assessments. All AEs were recorded in the case report form.
Traditional pharmacokinetic and pharmacodynamic assess-
ments were not possible as part of this study because of the nature
of the IMP. Disease activity was defined using physician’s global
assessment (PGA) and the weighted pediatric CD activity index
(wPCDAI) (19). All recruits provided written informed consent
for each part of the study.
Part A: single dose
Part A (see Supplementary Table 1, Supplementary Digital
Content 1, http://links.lww.com/AJG/B800) consisted of a
screening visit, within 28 days before dosing, when a check was
made of the subject’s ability and willingness to swallow 3 empty
size 0 placebo capsules. Three research visits were then required:
for single-dose treatment on day 0 (visit 1) and post-treatment
visits on day 1 (visit 2) and day 7 (visit 3).
Subjects were requested to have a light breakfast 2 hours before
attending the clinic. Subjects received a single oral dose (3 cap-
sules) of Thetanix or placebo. No food was allowed for 4 hours
after dosing, although water was freely available. This step was
undertaken to normalize dosing conditions across the study.
Subjects were assessed (vital signs andAEs) at 2, 4, and 8 hours
postdosing and then discharged. Subjects completed electronic
diaries including the recording of body temperature orally twice
daily for 7 days alongside any side effects. Body temperatureswere
taken on electronic thermometers provided by the sponsor.
Subjects were instructed to contact the research site if they
developed a fever (2 body temperature recordings$38.0°C in 12
h or a single temperature $38.5°C) to arrange an unscheduled
assessment and blood cultures.
A baseline stool was collected in the 72 hours before day 0, and
a post-treatment stool from 48 hours after dosing. Stool samples
were collected in part A as a proof of principle for the method
deployed in part B.
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Box 1. Inclusion and exclusion criteria for the Thetanix study
Inclusion criteria
1. Subjects aged 16–18 yr inclusive with a confirmed diagnosis of Crohn’s disease (CD) who were in clinical remission* in the opinion of the investigator and who
were otherwise healthy.
2. Subjects who were able and willing to give written informed consent to participate and, if applicable, whose parent/carer gave consent to their participation.
*Remission was defined as all of the following 3 criteria being met:
(i) physician’s global assessment that the subject was in remission,
(ii) weighted pediatric CD activity index #12.5, and
(iii) no clinically significant, in the opinion of the investigator, elevations of platelets, white cell count, C-reactive protein (CRP), or erythrocyte sedimentation rate
(ESR) and no clinically significant decrease in albumin or hemoglobin.
Exclusion criteria
1. Subjects who were pregnant or breastfeeding.
2. Subjects who were experiencing an exacerbation at the time of screening or up to the time of the first dose.
3. Subjects who had undergone previous surgery for resection of bowel. (Subjects who had had surgery for perianal abscess more than 6 mo before dosing
remained eligible.)
4. Subjects who had active fistulation.
5. Subjects who had a significant change in their immune-modulating maintenance medication in the 3 mo before screening and/or the start of dosing.
6. Subjects who had taken systemic steroids in the past 3 mo. Rectal and inhaled steroid use was permitted.
7. Subjects who were unable to take any oral feeding.
8. Subjects with feeding gastrostomies.
9. Subjects who had nonfood dietary supplementation changed for any reason within 1 mo before dosing.
10. Subjects who had received monoclonal antibodies in the 6 mo before dosing.
11. Subjects who had received antibiotics or probiotic dietary supplementation in the 2 wk before dosing. Subjects who had received foods with probiotics e.g.,
yoghurts were permitted to volunteer for the study.
12. Subjects who were receiving exclusive enteral feeding or had completed a course of exclusive enteral feeding in the 3 mo before dosing.
13. Subjects with concomitant autoimmune diseases (e.g., type 1 diabetes, juvenile arthritis, and psoriasis).
14. Female subjectsof child-bearingpotential unwilling touseeffectivecontraception from thesigningof the informedconsent formuntil completionof2periodsafter the last
dose. Aneffectivemethodof birth controlwasdefinedasonewhich resulted in a low failure rate (i.e., less than1%per year)whenusedconsistently andcorrectly suchas
sterilization, implants, injectable, combined oral contraceptives, intrauterine device, condoms, and occlusive caps (cervical/vault caps) with spermicidal foam/gel/film/
cream/pessary. True sexual abstinence was acceptable when this was in line with the preferred and usual lifestyle of the subject (periodic abstinence e.g., calendar,
ovulation, symptothermal, postovulationmethods, declaration of abstinence for the duration of the trial, andwithdrawal were not acceptablemethods of contraception).
15. Subjects with clinically significant, in the opinion of the investigator, elevations in platelets, white cell count, CRP, ESR, low albumin, or hemoglobin.
16. Subjects who were positive for the following viruses: HIV and hepatitis B or hepatitis C.
17. Subjects who smoked cigarettes or used other tobacco or nicotine containing produces, including e-cigarettes.
18. Subjects who had known sensitivity to any of the constituents of the investigational medicinal compound.
19. Diastolic bloodpressure,50or.90mmHg, a systolicbloodpressure,100or.150mmHg, apulse,40or.100beatsperminute (bpm)after resting for 5min.
20. Subjects with clinically significantly abnormal ECGs or structural cardiac abnormalities e.g., valvular heart disease, patent foramen ovale.
21. Body mass index Z score less than 22.6 or greater than 2.6 (06 2.6); i.e., below the second centile or greater than the ninety-eighth centile.
22. Any condition that, in the opinion of the investigator, might interfere with the primary study objective.
23. Subjects allergic to metronidazole and co-amoxiclav.
Exclusion criteria amended 18/12/16 to facilitate recruitment as follows:
3. Subjects who had undergone surgery for resection of bowel in the past 12 mo, or subjects who had undergone resection of bowel more than 12 mo ago, and
subjects who had experienced an exacerbation in the past 12 mo or developed fistulae. (Subjects who had resection of bowel more than 12 mo ago, with no
further requirement for surgery within the past 12mo, with stablemedications as per other inclusion/exclusion criteria and subjects who had surgery for perianal
abscess more than 6 mo before dosing remained eligible.)
10. Subjects who were receiving a dose of monoclonal antibodies that had required adjustment because of clinical indications relating to their underlying CD and
therefore had not beenwithin a stable dosing range (e.g., 5mg/kg 8weekly, allowing for changes in subject weight) for the past 12moorwho had evidence of an
exacerbation. (Note: subjects who had missed or delayed occasional doses of monoclonal antibodies due to intercurrent illness, unavailability, examinations,
holidays, other extraneous, or nonclinical reasons during the 12 mo remain eligible, providing the overall dosing regimen would have provided stable longer-
term circulating drug levels in the opinion of the investigator.)
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Pediatric Phase I Thetanix 3
All clinical and laboratory data from part A was reviewed by
the SRC before proceeding to part B.
Part B: multiple doses
After approval from the SRC, part B recruitment commenced
(Table 1). Subjects who participated in part Awere also allowed to
participate in part B if they wished, after rescreening and recon-
senting, for pragmatic recruitment purposes. For subjects that did
not participate in the single-dose phase, a check was made of the
subject’s ability and willingness to swallow 3 empty size 0 placebo
capsules at screening.
Part B consisted of a screening visit, within 28days before dosing
and 5 research visits to commence treatment on day 0 (visit 1), a
safety check 24 hours later on day 1 (visit 2), visits 7 and 14 days
postday 0 (visits 3 and 4), and a final follow-up at day 56 (visit 5).
PartBtreatmentconsistedofa twicedailydosingperiodofThetanix
or placebo (an hour before food) every 12 hours for 7.5 days. The first
dosewas taken in the clinic; the next 13 doses were taken at home, and
the 15th dose was also taken in the clinic. The first and last doses were
observed in the research facility, eachwith a4-hour stay afterward,with
blood pressure and temperature checks at 2- and 4-hours postdosing.
Subjects completed electronic diaries at home for 14 days
after commencing treatment on day 0 (visit 1). The diaries
collected the same information as in part A and subjects also
recorded the times they took their study medication. Subjects
were given access to electronic diaries in which to record body
temperature twice daily, this time for 14 days, alongside any
side-effects experienced and instructed to contact the research
site if they developed a fever to arrange an unscheduled as-
sessment and blood cultures.
Clinical disease activity indices were obtained on up to 6 oc-
casions and blood sampling was undertaken on 4 (see Supple-
mentary Table 1, Supplementary Digital Content 1, http://links.
lww.com/AJG/B800 and Table 1). Vital signs and a medication
check were undertaken during all visits. Three stool samples were
requested—a baseline stool in the 72 hours before day 0, a post-
treatment stool from the 48 hours after day 7, and a follow-up
stool in the in the 72 hours before day 56.
The following parameters were evaluated over the course of the
study: vital signs, height, weight, and calculation of body mass
index z scores; calculation of PGA and wPCDAI scores; laboratory
findings, fecal calprotectin (part B only), and stool microbiota.
Table 1. Schedule of events for the multiple-dose Thetanix study (part B)
Assessment
Screening: day228
to day21 Visit 1: day 0 Visit 2: day 1 Visit 3: day 7
Visit 4:
day 14 Visit 5: day 56
Informed consent X
Inclusion/exclusion criteria X X
Medical history X
Concomitant medication X X X X X X
Height/weight X X X X X X
Vital signs (BP, HR, RR and temperature) X Xa X Xa X X
Full physical examination X
HIV/hepatitis B and C screen X
Electrocardiogram X
Hemoglobin X X X
Clinical chemistry X X X X
Blood cultureb X
wPCDAI X X X X X X
Physician’s global assessment X X X X
Brief physical examination X X X
Stool sample Xc Xd Xc
Admission for 4 h X X
Randomization X
Dosinge XX
Urine pregnancy test X X
Adverse events Xa X Xa X X
BP, blood pressure; HR, heart rate; RR, respiratory rate; wPCDAI, weighted pediatric Crohn’s disease activity index.
aPredose and 2 and 4 hours postdose.
bIf clinically indicated due clinical suspicion of infection or fever .38.5°C on 1 occasion or .38.0°C 32 in a 12-hour period.
cStool sample collected within 72 hours before the visit.
dStool sample collected within 48 hours of the last dose of each 7.5-day twice daily administration.
eDosing, 3 capsules twice daily for 7.5 days (total of 15 doses).
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Laboratory
Routine hematology and serum biochemistry testing (full blood
count, erythrocyte sedimentation rate, urea and electrolytes, liver
function tests, bone profile, and C-reactive protein) was un-
dertaken within accredited hospital laboratories linked to the
research sites where subjects were recruited.
Subjects were provided with stool collection kits and in-
structions and asked to send samples to a central laboratory. Each
stool sample was split in 2 by participants before posting. One
sample was placed into a plain universal container for calpro-
tectin analysis and another into the stool collection tube complete
with stabilization buffer produced by Invitek Molecular GmbH
(Berlin, Germany) for microbiome work.
Statistical analysis
Analysis of clinical variables was undertaken in Microsoft Excel
2019 and IBMSPSS Statistics Version 26. Analysis ofmicrobiome
data is described in Supplementary Methods (see Supplementary
Digital Content 1, http://links.lww.com/AJG/B800).
Ethical considerations
Ethics committee approval was received for the study (Ref: 15/
WS/0166). The study was registered on ClinicalTrials.gov (Ref:
NCT02704728) and EduraCT (Ref: 2014-005666-29). Subjects
were paid £100 for participation in part A and £200 for part B as
agreed by the ethics review committee.
Details on fecal calprotectin, microbiome, and real-time
polymerase chain reaction (RT-PCR) analyses are provided in
Supplementary Methods (see Supplementary Digital Content 1,
http://links.lww.com/AJG/B800).
RESULTS
In total, 23 subjects were screened for this study—10 in partA and
13 in part B. Eight completed part A (6 active and 2 placebo) and
10 completed part B (8 active and 2 placebo; Table 2). One subject
was excluded from part A because of nonavailability of the IMP
and the other failed screening. Three screened subjects were ex-
cluded from part B—one failed screening, one attended screening
but cancelled their dosing visit, and one withdrew consent after
screening.
Recruits to partAwere 75%male patients with amedian age of
17.1 years at randomization (range 16.1–18.2 years), whereas
those in part B were 80% male patients with a median age of 17.1
years (range 16.4–18.2 years). Three participants completed both
part A and part B.
All participants were on concomitant medication. Immuno-
modulators were prescribed in 75% of part A participants (66.7%
active and 100% placebo) and anti-TNFa in 37.5% of part A
(33.3% active and 50% placebo). Concomitant IBD therapy in
part B is outlined in Table 2.
Treatment compliance was not measured in part A because
the IMP was administered under direct supervision. Reported
treatment compliance in part B was 99%, with one subject on
active Thetanix reporting 14/15 doses and all others reporting full
compliance.
Safety
A summary of all AEs is reported in Table 3. No serious AEs or
deaths occurred within the study. TwoThetanix recipients in part
A reported 4 AEs in total (abdominal pain, eructation, flatulence,
and gastroesophageal reflux). The eructation, flatulence, and
Table 2. Participant demographics for the multiple-dose Thetanix study (part B)
Basic demographics Thetanix multiple dose (N 5 8) Placebo (N 5 2) Total (N 5 10)
Age median 17.1 17.2 17.1
Min, max 16.4, 18.2 16.4, 17.9 16.4, 18.2
Sex
Male 6 (75%) 2 (100%) 8 (80%)
Female 2 (25%) 0 2 (20%)
Race
Black or African 0 0 0
American 0 0 0
American Indian or Alaska Native 0 0 0
Asian 0 0 0
White 8 (100%) 2 (100%) 10 (100%)
Concomitant therapy
No. of subjects with at least 1 concomitant
medication
8 (100%) 2 (100%) 10 (100%)
5-ASA 1 (12.5%) 1 (50%) 2 (20%)
Thiopurine 6 (75%) 0 6 (60%)
Methotrexate 1 (12.5%) 0 1 (10%)
Anti-TNF solo 1 (12.5%) 1 (50%) 2 (20%)
Anti-TNF combo 5 (62.5%) 0 5 (50%)
5-ASA, 5-aminosalicylic acid; TNF, tumor necrosis factor.
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Pediatric Phase I Thetanix 5
gastroesophageal reflux in one participant were deemed
treatment related by an investigator. Neither of the part A
placebo recipients reported any AEs. All PGA scores were
“quiescent” in part A. wPCDAI scores in part A ranged from
0 to 20. All scores were in remission apart from one placebo-
treated recruit who scored 20 at the baseline visit, but not at
screening (Table 4).
Four active recipients in part B reported 8 AEs in total (3 in-
stances of abdominal pain, one each of back pain, diarrhea,
nasopharyngitis, dizziness, and headache). The dizziness, ab-
dominal pain, and headache in one participant were deemed
treatment related by an investigator. One placebo recipient in part
B reported rhinitis, headache, and abdominal pain, which was
deemed unrelated.
All pregnancy tests undertaken were negative. All HIV and
hepatitis screens were negative. There were no clinically mean-
ingful changes in vital signs, ECG recordings, or hematology/
biochemistry results during the study. Importantly, no subject
had a raised temperature during the study, and hence, no blood
cultures and no antibiotic courses were required.
All PGA scores in part B were marked “quiescent” or “mild.”
One subject had a rating of “mild” at baseline, but not at screening
nor at day 56 (visit 5), whereas one had a baseline assessment of
“quiescent” and was marked “mild” at day 56. All other assess-
ments were “quiescent.” Full wPCDAI data are presented in
Table 4; however, scores ranged from 0 to 20 in part B, with all
scores achieving remission (,12.5) throughout the studywith the
exception of one baseline score of 20, in a participant with a
remission score at screening, and one day 56 (visit 5) score of 17.5,
both in the active group.
Thirteen of 16 (81%) possible stool samples from part A and
29/30 (97%) stools from part B were received. The 4missing stool
samples comprised one each from part A active day 0, part A
active day 1, part A placebo day 0, and part B active day 56.
There was no significant change inmedian calprotectin values
across 5 visits in part B—87.8 (range 4.4–447) to 50.5 (range
5.3–572), P5 1.00 by the Fisher exact test in the active group and
64.6 (range 14.9–114.3) to 123.5 (range 8.2–238.8), P 5 1.00 in
the placebo group. Calprotectin summary data are presented in
Table 5 and Supplementary Figure 1 (see Supplementary Digital
Content 1, http://links.lww.com/AJG/B800).
All 42 stool samples were sequenced for microbiome analysis.
81,672 6 12,704 reads were generated per sample. Microbiome
analysis demonstrated no significant differences between active
and placebo groups by Bray-Curtis dissimilarity in part B at days
0, 7, and 56 (Figure 1a–c).
Part A allowed exploration of diversity changes in the active
treatment group across a shorter time period (day 0 to day 1)
than part B (day 0 to day 7 and day 56) (Figure 2). There was no
significant difference inmicrobiota diversity for the active group
in part A (observed P value5 0.236, Shannon P value5 0.140)
from day 0 to day 1. Shannon diversity was however found to be
significantly different (observed P value 5 0.436, Shannon P
value 5 0.023) across the study time points in part B with an
increase in diversity from day 0 to day 7 which decreased at
day 56.
Microbiota evenness was also explored in the active group by
the Shannon diversity index (see Supplementary Figure 2, Sup-
plementary Digital Content 1, http://links.lww.com/AJG/B800).
A nonsignificant increase in microbiota evenness was observed
across the time points in part A (day 0 to day 1, P5 0.07), and a
significant difference was observed in part B (P5 0.03) across the
study timepointswith an increase in evenness fromday 0 to day 7,
which decreased again at day 56.
Table 3. Summary of the recorded adverse events in the Thetanix study (parts A and B)
Part A Part B
Thetanix single
dose (N 5 6)
Placebo
(N 5 2)
Total
(N 5 8)
Thetanix multiple
dose (N 5 8)
Placebo
(N 5 2)
Total
(N5 10)
No. of adverse events
recorded
4 0 4 8 3 11
Gastrointestinal 2 (33.3%) 0 2 (25%) 3 (37.5%) 1 (50%) 4 (40%)
Abdominal pain 1 (16.7%) 0 1 (12.5%) 2 (25%) 0 2 (20%)
Eructation 1 (16.7%) 0 1 (12.5%) 0 0 0
Flatulence 1 (16.7%) 0 1 (12.5%) 0 0 0
Reflux 1 (16.7%) 0 1 (12.5%) 0 0 0
Abdominal pain 0 0 0 1 (12.5%) 1 (50%) 2 (20%)
Diarrhea 0 0 0 1 (12.5%) 0 1 (10%)
Infections 0 0 0 1 (12.5%) 1 (50%) 2 (20%)
Nasopharyngitis 0 0 0 1 (12.5%) 0 1 (10%)
Rhinitis 0 0 0 0 1 (50%) 1 (10%)
Musculoskeletal 0 0 0 1 (12.5%) 0 1 (10%)
Back pain 0 0 0 1 (12.5%) 0 1 (10%)
Neurological 0 0 0 1 (12.5%) 1 (50%) 2 (20%)
Headache 0 0 0 1 (12.5%) 1 (50%) 2 (20%)
Dizziness 0 0 0 1 (12.5%) 0 1 (10%)
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No significant differences were seen in temporal microbiome
stability in part A or part B active or placebo groups (data not
shown). No significant differences were seen in taxa abundance
or functional pathway abundance across part B (data not
shown).
All 42 stool samples and 2 spike-in positive control samples
were screened for B. thetaiotaomicron by RT-PCR (see Supple-
mentary Table 2, Supplementary Digital Content 1, http://links.
lww.com/AJG/B800). B. thetaiotaomicron was identified in the
positive controls but was only identified in 5 (11.9%) samples;
hence, further analysis of these data was not possible. RT-PCRwas
positive for B. thetaiotaomicron in one placebo recipient in part A.
DISCUSSION
Our study provides evidence of the tolerability and safety
of B. thetaiotaomicron. Reported compliance with therapy was
high, there were no serious AEs, and the 2 participants who
Table 4. Summary of weighted pediatric Crohn’s disease activity index scores for the Thetanix study (parts A and B)
Part A Part B
Thetanix single dose (N 5 6) Placebo (N5 2) Total (N 5 8) Thetanix multiple dose (N 5 8) Placebo (N 5 2) Total (N 5 10)
Screening, n 6 2 8 8 2 10
Median (Q1–Q3) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Min, max 0, 5 0 0, 5 0, 7.5 0 0, 7.5
Baseline, n 6 2 8 8 2 10
Median (Q1–Q3) 0 (0–3.8) 10 (5–15) 0 (0–5) 0 (0–1.9) 0 (0–0) 0 (0–0)
Min, max 0, 5 0, 20 0, 20 0, 20 0 0, 20
Visit 2, n — — — 8 2 10
Median (Q1–Q3) — — — 0 (0–0) 0 (0–0) 0 (0–0)
Min, max — — — 0, 7.5 0 0, 7.5
Visit 3, n 6 2 8 8 2 10
Median (Q1–Q3) 5 (1.3–8.8) 5 (2.5–7.5) 5 (0–10) 0 (0–1.3) 0 (0–0) 0 (0–0)
Min, max 0, 10 0, 10 0, 10 0, 5 0 0, 5
Visit 4, n — — — 8 2 10
Median (Q1–Q3) — — — 0 (0–0) 0 (0–0) 0 (0–0)
Min, max — — — 0, 7.5 0 0, 7.5
Visit 5, n — — — 8 2 10
Median (Q1–Q3) — — — 0 (0–2.5) 0 (2.5–7.5) 0 (0–7.5)
Min, max — — — 0, 17.5 0, 10 0, 17.5
Q, quartile.
Table 5. Summary of fecal calprotectin in the multiple-dose Thetanix study (part B)
Part B
Thetanix multiple dose (N 5 8) Placebo (N5 2) Total (N 5 10)
Day 0, n 7 2 9
Median (Q1–Q3) 87.8 (24.9–215.9) 64.6 (39.8–89.5) 87.8 (14.9–149.2)
Min, max 4.4, 447.0 14.9, 114.3 4.4, 447.0
Day 7, n 7 2 9
Median (Q1–Q3) 112.8 (13.4–166.7) 45.85 (28.1–63.6) 81.3 (10.4–121.5)
Min, max 5.3, 572.0 10.4, 81.3 5.3, 572.0
Day 56, n 7 2 9
Median (Q1–Q3) 50.5 (19.6–204.7) 123.5 (65.9–181.2) 50.5 (18.8–238.8)
Min, max 5.3, 294.0 8.2, 238.8 5.3, 294.0
Stool samples were collected before the first dose, up to 48 hours after the last dose and in the 72 hours before day 56 in part B.
Q, quartile.
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suffered treatment-associated AEs had minor, self-limiting
symptoms that did not require specific treatment nor cessation
of the trial. In these patients with CD in remission, there was no
increase in wPCDAI or PGA during the study, and there was no
significant change in calprotectin levels in part B.
This first-in-humans phase I study of the novel live bio-
therapeutic (next-generation probiotic) B. thetaiotaomicron
represents a rarity within the medical literature. We have tradi-
tionally considered 4 phases of drug-based research in
humans—from phase I safety to phase IV postmarketing
Figure 1. Microbiota profiles of treatment groups in the multiple-dose Thetanix study (part B) on days 0, 7, and 56 based on Bray-Curtis Dissimilarities.
(a) Day 0 (n 5 10), (b) day 7 (n 5 10), and (c) day 56 (n 5 9). G1, active treatment; G2, placebo; PCoA, principle components analysis. No significant
differences were found in microbiota profiles between the groups at day 0 (P5 0.09), day 7 (P5 0.589), or day 56 (P5 0.299) in part B.
Figure 2. Effect of Thetanix on microbiota diversity in part A and part B using observed species and Shannon Metrics.
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surveillance (Table 6)—but previous clinical studies of probiotics
in IBD have generally not followed the same path, with reported
studies often being more associated with phase II or phase III
than the exploration of safety. Importantly, our study was de-
liberately small and was designed as a preliminary investigation
of safety and tolerability in a young population with known
disease. It was therefore underpowered to explore dosing, effi-
cacy, or mechanisms. Exploration of these factors will be a fun-
damental component of follow-on phase II studies and beyond.
As we explore more novel agents in distinct settings, particularly
as we seek to look at the biological utility of an organism to
provide or supplement a function rather than simply to colonize a
niche, there is a need to revisit our conventional approach to the
testing of drug-based therapies and to adjust this for the study of
novel microbial agents. There are significant and specific issues
related to the study of live organisms as therapy that are not easily
mapped to the traditional phases of drug-based research (ex-
panded in Table 6), most notably in the assessment of their
pharmacokinetic and pharmacodynamic properties. This has an
important impact on the exploration of both dosing and the
monitoring of therapeutic “levels” of the organism in question.
Specifically, we cannot prove nonefficacy of a live biotherapeutic
if we cannot determine adequate dosing or adequate uptake of the
organism in the appropriate niche. The converse is of course not
true; hence, in situations where clinical efficacy is proven, these
aspects can be assumed, but there is a danger of discarding live
biotherapeutics for nonefficacy without first addressing these
fundamental components.
Our study of the impact of Thetanix on the human fecal
microbiome was largely exploratory; the return rate of stool
samples was high (81% and 97%), and there was no significant
impact on overall microbial composition, temporal microbiome
stability, taxa abundance, or functional pathway abundance
during the study. The significant changes in Shannon diversity
and evenness in the active arm of part B are preliminary and need
replication in a larger phase II efficacy study to better understand
their relevance for a broader mechanism of action.
Our poor pick-up rate of B. thetaiotaomicron in fecal samples by
RT-PCR warrants discussion—clearly, this was a first attempt at
demonstrating positive colonization by a noninvasive, reproducible,
and relatively inexpensive laboratory assay. We have explored the ef-
ficacy of this assay in the laboratory setting and demonstrated high
sensitivity for pick-up of the same strain of B. thetaiotaomicron in-
cluding with spiked samples of fecal DNA from this study. We are
therefore confident that this result is a true negative to the limits of the
test becausewe did detect the organism in some samples, and so, it was
not entirely absent.There are several possibilities that could explain this
observation—transit of the organism is not reflected in our stool col-
lection timing, so we are missing it; our dose is insufficient for fecal
excretion andmayneed tobe higher ormore frequent; participants did
not take the therapy despite reporting compliance (which seems un-
likely, given the pervasiveness of low pick-up); the organism is being
degraded by gastric acidity or during transit through the gut; or all the
administered B. thetaiotaomicron is colonizing and so not being ex-
creted. Studying the latter would require before/after biopsies of the
colon that would not be ethically acceptable in children and would be
Table 6. Specific considerations for live biotherapeutic research in humansmapped alongside traditional phases of drug research (27,28)
Phase Purpose Length of study Usual participants in drug-based study Challenges with study of live biotherapeutics
I Safety and dosage Several months Usually,100 healthy volunteers or people
with the disease/condition
If the organism is resident in the healthy gut, is it
worth testing there?
Should we routinely measure effect on the
resident microbiome and, if so, how?
How do we define dose in a meaningful way
that is related to efficacy? (standard
pharmacokinetics and pharmacodynamics do
not apply)
What is the optimal route of administration for
the organism(s) in question?
How do we accurately measure successful
colonization/engraftment to contrast this with
efficacy?
II Efficacy and side-effects Several months to 2 yr Up to several hundred people with the
disease/condition
Identification of treatment candidates at the
most appropriate stage of disease for
intervention
Need to consider pre- and post-treatment
supportive therapies (antibiotics, diet,
prebiotics, etc.)
III Efficacy and monitoring
of adverse reactions
1–4 yr 300 to 3,000 volunteers who have the
disease or condition
Need to consider maintenance dosing and
supportive therapy—is the same dose required
long term if colonization/engraftment occur?
IV Safety and efficacy Long-term Several thousand volunteers who have the
disease/condition
Need to consider unforeseen longer-term
effects on the host via the microbiome e.g.,
obesity, inflammatory bowel disease, and
colorectal cancer
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hard to justify in an adult study in the absence of monitoring active
disease. Stool samples areatbest a surrogate formeasuringcolonization
with probiotics, and hence, poor detection in this medium does not
infer no colonization. Follow-on studies should specifically explore
dosing and whether there is a dosing threshold above which B. the-
taiotaomicron isdetectable in stool.Apotential alternativeapproach for
exploration of colonization in follow-on studieswould be evaluation of
the mechanistic impact of the organism on fecal metabolomics and
markers of gut inflammation such as cytokine levels, particularly
TNFa.All blood samplingandanalysis in this studywasundertaken in
hospital laboratories local to recruitment, and hence, serum TNFa
monitoringwasnotpossible in this earlyphase study.Thiswouldbe an
interesting biomarker to explore in follow-on research.
On the subject of dosing, B. thetaiotaomicron is a symbiont
in the bowel of healthy humans and can be detected in stool at
an average concentration of 1.39 3 108 CFUs/g of feces (20).
The median passage of stool is 128 g/person/day (21); hence, a
healthy individual sheds a median 1.78 3 1010 B. thetaiotao-
micron each day. It has also been estimated that 6% of all
bacteria in the healthy human intestine are B. thetaiotaomicron
(22), which would equate to;63 1013 organisms. Limited data
exist in the literature on the prevalence of B. thetaiotaomicron
in the gut of patients with CD, but it does not seem to be
abundant (14,23,24). Importantly, however, Thetanix does not
aspire to replace an absent nor increase levels of a low-
prevalence organism, it is instead intended to provide a live
biotherapeutic source of a potentially beneficial anti-
inflammatory mechanism, mitigating against the high levels
of TNFa that have long been associated with CD inflammation
(25,26). The main objective therefore was to dose to reduce
inflammation in the gut by increasing B. thetaiotaomicron, and
hence its effects on the NF-kB signaling pathways and sub-
sequently TNFa. For this study, the dose administered was 3
capsules, each containing 107.7361.43 CFUs, therefore giving a
total daily dose of 108.2161.43 CFUs. Twice daily dosing for 7.5
days (15 doses) in part B would therefore give a cumulative dose
between 8.98 3 107 and 6.5 3 1010 CFUs. The viable bacterial
cell count is considered to be the key potency parameter for
Thetanix because the critical measure of activity was consid-
ered applicable for therapeutic effect. The chosen dose for this
study was, however, also pragmatically based on the maximum
number of viable bacteria that could be loaded into a capsule,
coupled with a realistic number of daily doses for the partici-
pants in the study that would be reproducible in clinical prac-
tice. Crossover was allowed between part A and part B in this
study, with 3 subjects undergoing further randomization in
part B. Crossover of a single-dose active product from part A
into the placebo arm of part B was therefore possible within the
study design. We did not control or analyze for this, given part
B was single dose and crossover was not immediate. Future
studies of Thetanix may need to explore higher doses or longer
durations of treatment if subsequent efficacy evaluations are
considered underdosed. As discussed above, ensuring adequate
biotherapeutic delivery is a key challenge within this emerging
field of therapeutic research.
B. thetaiotaomicron (as Thetanix) with twice daily doses over a
7.5-day dosing period is well tolerated by adolescents with CD
who are in remission. It does not result in significant AEs or
toxicity over this time period and does not detrimentally alter
clinical or laboratory parameters including fecal calprotectin.
Although exploratory, limited evidence points to a positive
effect on microbial diversity and evenness though, on the whole,
B. thetaiotaomicron had a limited impact on the host fecal
microbiota during this initial study. Future studies should explore
the optimum dose and duration of Thetanix and signals of its
efficacy as an induction and maintenance agent in CD.
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Study Highlights
WHAT IS KNOWN
3 The microbiome is important in Crohn’s disease
pathogenesis.
3 Probiotics have been disappointing as therapy for Crohn’s
disease to date, but most organisms studied have been
selected for convenience, availability, or ease ofmanufacture.
3 Bacteroides thetaiotaomicron attenuates gut inflammation
via antagonism of transcription factor NF-kB and subsequent
reduction of TNFa.
WHAT IS NEW HERE
3 B. thetaiotaomicron is a good candidate for translation to a
novel therapy as a potentially mucosally active anti-TNFa.
3 B. thetaiotaomicron as Thetanix is well tolerated with a
seemingly good safety profile.
3 wPCDAI and calprotectin were unaffected by Thetanix
dosing, but bacterial diversity seemed to increase in treated
subjects.
Clinical and Translational Gastroenterology VOLUME 12 | JANUARY 2021 www.clintranslgastro.com
IN
FL
A
M
M
A
TO
R
Y
B
O
W
EL
D
IS
EA
SE
Hansen et al.10
REFERENCES
1. McIlroy J, Ianiro G, Mukhopadhya I, et al. Review article: The gut
microbiome in inflammatory bowel disease—Avenues for microbial
management. Aliment Pharmacol Ther 2018;47(1):26–42.
2. Cohen LJ, Cho JH, Gevers D, et al. Genetic factors and the intestinal
microbiome guide development of microbe-based therapies for
inflammatory bowel diseases. Gastroenterology 2019;156(8):2174–89.
3. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have
shaped the genetic architecture of inflammatory bowel disease. Nature
2013;491(7422):119–24.
4. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive
faecal microbiota transplantation for active ulcerative colitis: A
randomised placebo-controlled trial. Lancet 2017;389(10075):1218–28.
5. Lai CY, Sung J, Cheng F, et al. Systematic review with meta-analysis:
Review of donor features, procedures and outcomes in 168 clinical studies
of faecal microbiota transplantation. Aliment Pharmacol Ther 2019;
49(4):354–63.
6. LevineA,KoriM,Kierkus J, et al. Azithromycin andmetronidazole versus
metronidazole-based therapy for the induction of remission in mild to
moderate paediatric Crohn’s disease: A randomised controlled trial. Gut
2019;68(2):239–47.
7. Swaminath A, Feathers A, Ananthakrishnan AN, et al. Systematic review
with meta-analysis: Enteral nutrition therapy for the induction of
remission in paediatric Crohn’s disease. Aliment Pharmacol Ther 2017;
46(7):645–56.
8. Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the
pathogenesis and treatment of inflammatory bowel diseases. Gut 2018;
67(9):1726–38.
9. Svolos V, Hansen R, Nichols B, et al. Treatment of active Crohn’s disease
with an ordinary food-based diet that replicates exclusive enteral
nutrition. Gastroenterology 2019;156(5):1354–67.
10. Derwa Y, Gracie DJ, Hamlin PJ, et al. Systematic review with meta-
analysis: The efficacy of probiotics in inflammatory bowel disease.
Aliment Pharmacol Ther 2017;46(4):389–400.
11. Sigall-Boneh R, Levine A, Lomer M, et al. Research gaps in diet and
nutrition in inflammatory bowel disease. A topical review by D-ECCO
working group [Dietitians of ECCO]. J Crohns Colitis 2017;11(12):
1407–19.
12. ShanahanF. Editorial: Probiotics in inflammatory bowel disease—Wrong
organisms, wrong disease, or flawed concepts? Aliment Pharmacol Ther
2017;46(6):632–3.
13. Porter NT, Luis AS, Martens EC. Bacteroides thetaiotaomicron. Trends
Microbiol 2018;26(11):966–7.
14. Kansal S, Catto-Smith AG, Boniface K, et al. The microbiome in
paediatric Crohn’s disease—A longitudinal, prospective, single-centre
study. J Crohns Colitis 2019;13(8):1044–54.
15. Wrzosek L, Miquel S, Noordine ML, et al. Bacteroides thetaiotaomicron
and Faecalibacterium prausnitzii influence the production of mucus
glycans and the development of goblet cells in the colonic epithelium of a
gnotobiotic model rodent. BMC Biol 2013;11:61.
16. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria
attenuate inflammation by regulating nuclear-cytoplasmic shutting of
PPAR-g and ReIA. Nat Immunol 2004;5(1):104–12.
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